Shuttle Pharma director Joseph Tung resigns

Shuttle Pharmaceuticals Holdings, Inc. reported that on September 11, 2025, director Joseph Tung resigned from its board of directors.

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. reported that on September 11, 2025, director Joseph Tung resigned from its board of directors. The company stated that Mr. Tung’s resignation was not the result of any disagreement that would require disclosure under the relevant SEC rules, indicating it was not tied to a reportable dispute over company operations, policies, or practices.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Shuttle Pharmaceuticals (SHPH) disclose in this 8-K filing?

Shuttle Pharmaceuticals disclosed that director Joseph Tung resigned from the board of directors on September 11, 2025.

Who resigned from Shuttle Pharmaceuticals Holdings, Inc. (SHPH)?

Board member Joseph Tung resigned as a director of Shuttle Pharmaceuticals Holdings, Inc..

When did Shuttle Pharmaceuticals director Joseph Tung resign?

Director Joseph Tung resigned on September 11, 2025, as disclosed in the report.

Was Joseph Tung’s resignation from SHPH due to a disagreement?

The company stated that Mr. Tung’s resignation was not the result of any disagreement that would require disclosure under Item 5.02(a).

What stock is associated with Shuttle Pharmaceuticals in this filing?

The filing lists Common Stock $0.00001 par value trading under the symbol SHPH on The Nasdaq Stock Market LLC.

Who signed the Shuttle Pharmaceuticals 8-K reporting this resignation?

The report was signed on behalf of the company by Christopher Cooper, who is identified as Interim Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/17/2025 - 04:26 PM EDT Learn about SEC filing dates

false 0001757499 0001757499 2025-09-11 2025-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41488		82-5089826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.00001 per share		SHPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 11, 2025, Joseph Tung resigned as a director of Shuttle Pharmaceuticals Holdings, Inc.

Mr. Tung’s resignation was not the result of any disagreement that would require disclosure under Item 5.02(a) of Form 8-K.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Dated: September 17, 2025
	By:	/s/ Christopher Cooper
	Name:	Christopher Cooper
	Title:	Interim Chief Executive Officer

3